Biotech RadarJobs updated

COMPANY

Xentria

HQ: Chicago, IL source · xentria.com ↗ · Midwest

Clinical Phase 2

Location: Chicago, IL · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Pulmonary Sarcoidosis Osteoporosis XTMAB-16 MAB-22 KM04

10Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations source ↗
  2. Trial start Phase 1: A Study to Investigate the Pharmacokinetics and Safety of KM04 Compared to United States (US)-Gonal-f Revised Formulation Female (RFF) Redi-ject and European Union (EU)-Gonal-f in Healthy Adu source ↗
  3. Trial start Phase 1: Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog® source ↗
  4. Trial start Phase 3: Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® source ↗
  5. Trial start Phase 1: Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus® source ↗
  6. Trial start Phase 1: Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid® source ↗
  7. Trial start Phase 1: Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® source ↗
  8. Trial start Phase 2: An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis source ↗
  9. Trial start Phase 1/Phase 2: Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations source ↗
  10. Trial start Phase 1: Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 10

RecordTitlePhaseStatusStartPrimary completion
NCT05890729Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary ManifestationsPhase 1/Phase 2Active, not recruitingNov 10, 2023Oct 31, 2026 (estimated)
NCT07680166An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary ManifestationsPhase 2Not yet recruitingOct 30, 2026Oct 31, 2029 (estimated)
NCT07794683A Study to Investigate the Pharmacokinetics and Safety of KM04 Compared to United States (US)-Gonal-f Revised Formulation Female (RFF) Redi-ject and European Union (EU)-Gonal-f in Healthy Adult Female VolunteersPhase 1Not yet recruiting2026-102027-03 (estimated)
NCT06169397An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary SarcoidosisPhase 2Active, not recruitingMar 1, 20242026-11 (estimated)
NCT07165652Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog®Phase 1CompletedOct 13, 2025Mar 2, 2026 (actual)
NCT06492226Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®Phase 1CompletedJul 30, 2024Oct 31, 2024 (actual)
NCT06310824Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®Phase 1CompletedJun 5, 2024Jul 22, 2025 (actual)
NCT06627478Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®Phase 1CompletedOct 29, 2024Jul 3, 2025 (actual)
NCT06504966Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®Phase 3Withdrawn2025-102027-10 (estimated)
NCT04971395Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult ParticipantsPhase 1CompletedJun 25, 2021Mar 18, 2022 (actual)
Feedback